Recently, the initial public offering of Funeng Technology (Ganzhou) Co., Ltd. ("Funeng Technology") was examined and approved by the Science and Technology Innovation Board Stock listing Committee of the Shanghai Stock Exchange, becoming the first share of Science and Technology Innovation Board's power battery. Kang Fang Biotechnology (Cayman) Co., Ltd. ("Kang Fang Bio") is expected to become the second unprofitable biotechnology company to list in Hong Kong this year through the Hong Kong Exchanges and Clearing listing hearing. BoCom International (03329) participated in the equity investments of the two companies as an investor and served as the joint global coordinator of Hong Fang's biological listing project.
In recent years, BoCom International adheres to the balanced development and coordinated promotion of asset business and licensed business, closely combines the major strategic needs of the country, actively serves the high-quality development of strategic emerging industries, and gives full play to the advantages of the investment banking business platform of BoCom Group. gather the group's comprehensive financial services resources, take equity investment as the starting point, and take the Bank of Communications Branch Fund as the lead. Provide "financing + intelligence" services for high-quality scientific and technological enterprises in the whole life cycle. Recently, three more BoCom international equity investment companies are planning to declare the listing on the gem board, and the financial enabling support effect is being released at an accelerated pace.
Recently completed equity investment project of BoCom International
Encourage flight in the cloudy sky
BoCom Kechuang Fund managed by BoCom International has completed its equity investment in Shenzhen Yuntian Lifei Technology Co., Ltd. ("Yuntian Lifei"), and continues to distribute the field of artificial intelligence.
Focusing on the field of visual intelligence, Yuntian Lifei is the first artificial intelligence company in China with key technologies such as AI algorithm, chip and big data platform, and has created a variety of products and solutions for public safety, social governance, new business, AIoT and other fields. Yuntian Deep eyes, the world's first dynamic portrait recognition system independently developed by the company, has been applied in more than 100 cities at home and abroad, such as Shenzhen, Qingdao, Chengdu, Changsha, Nanjing, Hangzhou, Shanghai, Beijing and so on. During the epidemic, the company launched an AI epidemic prevention and control program, which mainly uses AI technology capabilities such as face recognition, AI temperature measurement, historical trajectory analysis and relationship graph analysis to assist relevant departments in epidemic prevention and control work such as confirmed case tracking, suspected case prevention and control, public place management and mobile personnel control on the premise of protecting patients' and public privacy. The company's AI epidemic prevention and control equipment, "Deep eyes" system and "Tiantu" system were also included in the list of the first 34 artificial intelligence products and solutions issued by the Secretariat of the National artificial Intelligence Standardization Group.
Tianguang Shi
BoCom Science and Technology Fund managed by BoCom International has completed its equity investment in Beijing Tianguangshi Biotechnology Co., Ltd. ("Tianguangshi"), accelerating the layout of the biomedical field.
Tian Guangshi is a bio-pharmaceutical company in the clinical stage, with the leading domestic monoclonal antibody drug research and development and industrialization technology capabilities and formed a perfect technical system. The company focuses on the research and development and commercialization of biomacromolecular drugs with independent intellectual property rights, safety, effectiveness and meet the needs of the Chinese market, and is committed to becoming a Sino Biopharmaceutical enterprise with core products and sustainable innovation ability. Since its establishment in 2003, the company has established a rich pipeline of biological macromolecular products, with indications covering lung cancer, gastric cancer, lymphoma, leukemia, breast cancer, colorectal cancer, lupus nephritis, hyperlipidemia and emerging infectious diseases. Including China's first new generation of CD20 antibody MIL62, the world's first ADCC enhanced double anti-MBS301 and anti-Ebola virus antibody MIL77 and other products have won special support for the development of major new drugs in China.
About the Bank of China Kechuang Fund
In order to focus on the development of triangular integration and the construction of Science and Technology Innovation Board, BoCom International launched the establishment of BoCom Science and Technology Innovation Equity Investment Fund in Shanghai in April 2019, becoming China's first banking department venture equity investment fund. BoCom International serves as the fund manager, bringing together the resources of BoCom Group to connect Kechuang Board. BoCom Science and Technology Fund to "characteristics, branding, scale, benefit"-oriented, set up a regional sub-fund to expand the size of the fund, so far, science and technology fund investment covers cloud computing, big data, biomedicine, artificial intelligence and other key support industries of Science and Technology Innovation Board.